HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

3 late-stage MASH drugs that could rival Rezdiffra

The red-hot market has plenty of room for additional therapies from big-name players and clinical-stage companies alike.

By PharmaVoice · Jun 29, 2026 · via PharmaVoice

This is an aggregated industry headline. Read the full story at PharmaVoice →

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.

Tags
theweekformat:headlineheadlinePharmaVoice
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
BeOne's Brukinsa hits goal in mantle cell lymphoma confirmatory trial
A Brukinsa regimen has delivered a large progression-free survival benefit in what BeOne Medicines called a "n…
Jun 30, 2026
The WeekFierceBiotech ↗
Praxis faces FDA decision delay as analysts point finger at agency layoffs
The FDA has delayed a decision on the approval of Praxis Precision Medicine's rare epilepsy prospect by three …
Jun 30, 2026
FDA Updates List of Off-Patent Drugs Without Approved Generics
The WeekBriefing
FDA Updates List of Off-Patent Drugs Without Approved Generics
The FDA’s June 2026 update again highlights brand drugs still lacking generic challengers, aiming to spur ANDA…
Jun 30, 2026